Davis Polk advised the underwriters and the joint global coordinators in the public offering of BeiGene, Ltd. on the Hong Kong Stock Exchange. The gross proceeds from the offering amounted to approximately HK$7.08 billion (US$903 million) prior to the exercise of the over-allotment option.
BeiGene, Ltd. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immune-oncology drugs for the treatment of cancer. The ADSs of BeiGene, Ltd. are listed for trading on the NASDAQ under the symbol “BGNE.”
The Davis Polk corporate team included partners Bruce K. Dallas, Paul Chow and Bonnie Y. Chan, counsel Yang Chu, associates Jeffrey C. Lau, Josephine Chen, Dongbiao Shen and Barbara Wang and registered foreign lawyer Xuelin (Steve) Wang. Counsel Alon Gurfinkel and associate Omer Harel provided tax advice. Partner David R. Bauer and associate Tilak Koilvaram provided advice on intellectual property and technology matters. Members of the Davis Polk team are based in the Hong Kong, London, New York and Northern California offices.